Browsing Clinical Studies by author "Selfe, Joanna"
Now showing items 1-8 of 8
-
ATR Is a Therapeutic Target in Synovial Sarcoma.
Jones, SE; Fleuren, EDG; Frankum, J; Konde, A; Williamson, CT; et al. (AMER ASSOC CANCER RESEARCH, 2017-12-15)Synovial sarcoma (SS) is an aggressive soft-tissue malignancy characterized by expression of SS18-SSX fusions, where treatment options are limited. To identify therapeutically actionable genetic dependencies in SS, we ... -
Biological Role and Clinical Implications of MYOD1L122R Mutation in Rhabdomyosarcoma
Chisholm, J; Shipley, J; Selfe, J (MDPI AG, 2023-03-07) -
Biological Role and Clinical Implications of MYOD1L122R Mutation in Rhabdomyosarcoma.
Di Carlo, D; Chisholm, J; Kelsey, A; Alaggio, R; Bisogno, G; et al. (MDPI, 2023-03-07)Major progress in recent decades has furthered our clinical and biological understanding of rhabdomyosarcoma (RMS) with improved stratification for treatment based on risk factors. Clinical risk factors alone were used to ... -
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
Holme, H; Gulati, A; Brough, R; Fleuren, EDG; Bajrami, I; et al. (NATURE PUBLISHING GROUP, 2018-07-13)Osteosarcoma (OS) is an aggressive sarcoma, where novel treatment approaches are required. Genomic studies suggest that a subset of OS, including OS tumour cell lines (TCLs), exhibit genomic loss of heterozygosity (LOH) ... -
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.
Renshaw, J; Taylor, KR; Bishop, R; Valenti, M; De Haven Brandon, A; et al. (AMER ASSOC CANCER RESEARCH, 2013-08-05)PURPOSE: To provide rationale for using phosphoinositide 3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK) pathway inhibitors to treat rhabdomyosarcomas, a major cause of pediatric and adolescent cancer deaths. ... -
Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells.
Thway, K; Robertson, D; Jones, RL; Selfe, J; Shipley, J; et al. (NATURE PUBLISHING GROUP, 2016-08-09)BACKGROUND: Soft tissue sarcomas are a group of neoplasms with differentiation towards mesenchymal tissue, many of which are aggressive and chemotherapy resistant. Histology and immunoprofiles often overlap with neoplasms ... -
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
Shern, JF; Selfe, J; Izquierdo, E; Patidar, R; Chou, H-C; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2021-09-10)PURPOSE: Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond PAX-FOXO1 fusion ... -
Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.
Selfe, J; Olmos, D; Al-Saadi, R; Thway, K; Chisholm, J; et al. (WILEY, 2017-07-01)BACKGROUND: Long-term toxicities from current treatments are a major issue in paediatric cancer. Previous studies, including our own, have shown prognostic value for the presence of PAX3/7-FOXO1 fusion genes in rhabdomyosarcoma ...